The U.S. Food and Drug Administration recently approved Sanofi Pasteur’s request to include data in the prescribing information for its Fluzone High-Dose flu vaccine that shows it is more effective in protecting older patients.
A new study, published in the Aug. 14 issue of The New England Journal of Medicine, showed that Fluzone High-Dose protects better than Fluzone’s standard dose in adults 65 and older.
“Inclusion of these efficacy data in the Fluzone High-Dose vaccine prescribing information validates the importance of this vaccine for people 65 years of age and older,” Dr. David P. Greenberg, vice president for Scientific & Medical Affairs and chief medical officer of Sanofi Pasteur US, said. “We are fully committed to helping protect patients from influenza, and we urge everyone eligible—especially older adults—to get vaccinated as soon as possible if they have not already done so.”
Common Management Taxonomy: